Transfection of dendritic cells and methods therefor
AssigneesNant Holdings IP, LLC, NantCell, Inc.
InventorsPatrick Soon-Shiong, Kayvan Niazi
Life of this patent
Estimating the term…
Abstract
Immunotherapeutic methods and compositions are contemplated where one or more neoepitopes and/or tumor associated antigens are produced in, or delivered to dendritic cells, and in which so modified dendritic cells are co-cultured with immune competent cells of a patient, preferably in the presence of stimulatory signals. Cells are then transfused to the patient that has preferably undergone immune checkpoint inhibition treatment.
Claims36
A method of treating a patient having a tumor, comprising:
- administering to the patient a plurality of immune competent cells that were previously ex vivo exposed to transfected antigen-presenting cells;
- wherein the antigen-presenting cells were transfected with at least one patient-specific tumor neoepitope or an RNA or expression vector comprising a nucleic acid sequence that encodes the at least one patient-specific tumor neoepitope;
- and
- wherein the immune competent cells are obtained from the patient having the tumor.
(canceled)
4-7. (canceled)
(canceled)
12-18. (canceled)
(canceled)
22-23. (canceled)
A method of ex vivo activating immune competent cells from a patient having a tumor, comprising:
- obtaining from the patient a plurality of immune competent cells;
- transfecting ex vivo a plurality of antigen-presenting cells with at least one patient-specific tumor neoepitope or with an expression vector comprising a nucleic acid that encodes the at least one patient-specific tumor neoepitope;
- and
- co-culturing the plurality of immune competent cells with the plurality of transfected antigen-presenting cells for a time sufficient to activate the immune competent cells.
(canceled)
27-30. (canceled)
The method of claim wherein the at least one patient-specific tumor neoepitope is an HLA-matched patient-specific tumor neoepitope.
(canceled)
35-41. (canceled)
43-44. (canceled)
A pharmaceutical composition, comprising:
- a pharmaceutically acceptable carrier for transfusion in combination with a plurality of immune competent cells and a plurality of transfected antigen-presenting cells;
- wherein the antigen-presenting cells are cells transfected with at least one patient-specific tumor neoepitope or an expression vector comprising a nucleic acid that encodes the at least one patient-specific tumor neoepitope;
- and
- wherein the immune competent cells are obtained from the patient having the tumor.
(canceled)
48-51. (canceled)
(canceled)
56-62. (canceled)
65-85. (canceled)
Dependencies are inferred from the claim text.